ResearcherUniversity of VirginiaActive in the last 2 years

Xiaolong Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-1327-4061; OpenAlex author ID A5101617591. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.3390/biom15070948 ↗
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Co-author DOI 10.1073/pnas.2009899117 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

William J. Kane · 2 shared papers, 2020–2025 · strength 0.40
- Paper PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer. DOI 10.3390/biom15070948 ↗
- Paper Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic c… DOI 10.1073/pnas.2009899117 ↗
Todd W. Bauer · 2 shared papers, 2020–2025 · strength 0.40
- Paper PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer. DOI 10.3390/biom15070948 ↗
- Paper Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic c… DOI 10.1073/pnas.2009899117 ↗
Sarbajeet Nagdas · 1 shared paper, 2025 · strength 0.30
- Paper PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer. DOI 10.3390/biom15070948 ↗
Harun Öztürk · 1 shared paper, 2020 · strength 0.09
- Paper Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic c… DOI 10.1073/pnas.2009899117 ↗
Mazhar Adli · 1 shared paper, 2020 · strength 0.09
- Paper Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic c… DOI 10.1073/pnas.2009899117 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.